Analysis of laboratory parameters for optimal autologous peripheral blood stem cell collection from lymphoma and myeloma patients.

Jung Hee KongYoumi HuSun-Young KongSe-Na LeeHyeon-Seok EomHyewon LeeEunyoung LeeHyoeun Shim

Published in: Journal of clinical apheresis (2020)

HPC count is a potential surrogate marker for monitoring the starting time for PBSC collection. Applying cutoff values for the number of HPC and CD34+ cells may be clinically useful for optimizing the timing of PBSC collection.

Keyphrases

peripheral blood
stem cells
newly diagnosed
end stage renal disease
ejection fraction
induced apoptosis
bone marrow
cell cycle arrest
multiple myeloma